Celiac Disease: Advances in Treatment via Gluten Modification

Samantha Stoven, Joseph A. Murray, Eric Marietta

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Celiac disease (CD) is an autoimmune enteropathy that occurs in genetically susceptible individuals carrying the prerequisite genetic markers HLA DQ2 or DQ8. These genetic markers are present in approximately 30% of the population, and the worldwide prevalence of CD is estimated to be approximately 1%-2%. Currently a gluten-free diet is the only treatment for CD, but novel therapies aimed at gluten modification are underway. This review will discuss gluten-based therapies including wheat alternatives and wheat selection, enzymatic alteration of wheat, oral enzyme supplements, and polymeric binders as exciting new therapies for treatment of CD.

Original languageEnglish (US)
Pages (from-to)859-862
Number of pages4
JournalClinical Gastroenterology and Hepatology
Issue number8
StatePublished - Aug 2012


  • Autoimmune
  • Celiac
  • Gluten
  • Therapies
  • Treatment

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Celiac Disease: Advances in Treatment via Gluten Modification'. Together they form a unique fingerprint.

Cite this